Toggle Daily
Novo sues Lilly over weight-loss drug ads
July 21, 2026
Novo Nordisk sued Eli Lilly, saying Lilly's ad campaigns intentionally used outdated studies comparing Lilly's highest doses against lower doses of Novo's drugs.
BBC reports that Novo Nordisk has sued Eli Lilly, accusing the drugmaker of misleading advertising in the weight-loss market. The suit's central allegation, per BBC, is that Lilly's current campaigns intentionally selected outdated studies that compared Lilly's highest doses against lower doses of Novo Nordisk's medicines, a matchup Novo says stacks the comparison in Lilly's favor.
CNBC, Bloomberg, Reuters and the Wall Street Journal corroborate that account. Five outlets carry the story in all, each with its own angle on the same underlying filing, and none disputes the substance of what Novo alleges. Which outlet reported it first is not confirmed, and no single account leads the pack; the agreement across all five is the point.
The allegation itself is settled reporting: Novo made the claim, and every outlet carrying the story reports it the same way. What none of them can settle yet is the merits, since the accusation is Novo's and a court has not weighed it.
Still developing
The lawsuit's fate is unresolved: Lilly's formal response, any court schedule, and whether Novo's characterization of the ad studies holds up have yet to be reported.
How settled the reporting is
Sources
- BBC — Ozempic-maker Novo Nordisk sues rival Eli Lilly, accusing it of false advertising
- CNBC — Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising
- Reuters — Novo sues Lilly, claiming misleading ads in weight-loss drug battle
- WSJ — Novo Sues Rival Lilly Over Alleged False Advertising in Weight-Loss Ads